The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients

CompletedOBSERVATIONAL
Enrollment

72

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Chronic Kidney DiseaseDialysis
Interventions
DRUG

Human Papillomavirus Vaccine

The HPV vaccination will be administered by intramuscular injection in three separate 0.5mL doses. The recommended schedule is a 3-dose series with dose #2 and #3 administered 2 and 6 months after dose #1, respectively. The minimum interval between dose #1 and #2 of the vaccine is 4 weeks. The minimum recommended interval between dose #2 and #3 of the vaccine is 12 weeks.

Trial Locations (1)

46202

Indiana University/Riley Children's Hospital, Indianapolis

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

National Kidney Foundation, United States

OTHER

lead

Indiana University

OTHER

NCT00767897 - The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients | Biotech Hunter | Biotech Hunter